Comparison of pirarubicin-based versus gemcitabine-docetaxel chemotherapy for relapsed and refractory osteosarcoma: A single institution experience

International Journal of Clinical Oncology

Volumn 18, Issue 3, 2013, Pages 498-505

  He, Aina ^a   Qi, Weixiang ^a   Huang, Yujing ^a   Sun, Yuanjue ^a   Shen, Zan ^a   Zhao, Hui ^a   Yang, Yumei ^a   Yao, Yang ^a  

^a SHANGHAI JIAO TONG UNIVERSITY   (China)

Author keywords

Cisplatin; Docetaxel; Gemcitabine; Ifosfamide; Osteosarcoma; Pirarubicin

Indexed keywords

DOCETAXEL; GEMCITABINE; PIRARUBICIN;

ADULT; AGED; ALOPECIA; ANEMIA; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER RECURRENCE; CANCER SURVIVAL; CHEMOTHERAPY INDUCED EMESIS; COMPUTER ASSISTED TOMOGRAPHY; CONTROLLED STUDY; DISEASE SEVERITY; DRUG EFFICACY; DRUG FATALITY; DRUG RESPONSE; DRUG SAFETY; FATIGUE; FEASIBILITY STUDY; FEMALE; HUMAN; KIDNEY DYSFUNCTION; LEUKOCYTE COUNT; LEUKOPENIA; LIVER DYSFUNCTION; MAJOR CLINICAL STUDY; MALE; MULTIPLE CYCLE TREATMENT; NAUSEA; NEUTROPENIA; NUCLEAR MAGNETIC RESONANCE IMAGING; OSTEOSARCOMA; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; RECURRENT CANCER; SALVAGE THERAPY; SIDE EFFECT; SURVIVAL TIME; THROMBOCYTE COUNT; THROMBOCYTOPENIA;

ADOLESCENT; ADULT; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BONE NEOPLASMS; CHILD; DEOXYCYTIDINE; DISEASE-FREE SURVIVAL; DOXORUBICIN; DRUG-RELATED SIDE EFFECTS AND ADVERSE REACTIONS; FEMALE; HUMANS; IFOSFAMIDE; KAPLAN-MEIER ESTIMATE; MALE; MIDDLE AGED; OSTEOSARCOMA; PROSPECTIVE STUDIES; TAXOIDS;

EID: 84879411370     PISSN: 13419625     EISSN: 14377772     Source Type: Journal    
DOI: 10.1007/s10147-012-0409-5     Document Type: Article

References (25)

1. Arndt CA, Crist WM (1999) Common musculoskeletal tumors of childhood and adolescence. N Engl J Med 341:342-352
2. Ottaviani G, Jaffe N (2009) The epidemiology of osteosarcoma. Cancer Treat Res 152:3-13
3. Friedman MA, Carter SK (1972) The therapy of osteogenic sarcoma: current status and thoughts for the future. J Surg Oncol 4:482-510
4. Ozaki T, Flege S, Kevric M et al (2003) Osteosarcoma of the pelvis: experience of the Cooperative Osteosarcoma Study Group. J Clin Oncol 21:334-341
5. Saeter G, Hoie J, Stenwig AE et al (1995) Systemic relapse of patients with osteogenic sarcoma. Prognostic factors for long term survival. Cancer 75:1084-1093
6. Tabone MD, Kalifa C, Rodary C et al (1994) Osteosarcoma recurrences in pediatric patients previously treated with intensive chemotherapy. J Clin Oncol 12:2614-2620
7. Okuno S, Edmonson J, Mahoney M et al (2002) Phase II trial of gemcitabine in advanced sarcomas. Cancer 94:3225-3229
8. McTiernan A, Whelan JS (2004) A phase II study of docetaxel for the treatment of recurrent osteosarcoma. Sarcoma 8:71-76
9. Navid F, Willert JR, McCarville MB et al (2008) Combination of gemcitabine and docetaxel in the treatment of children and young adults with refractory bone sarcoma. Cancer 113:419-425
10. Cortes EP, Holland JF, Wang JJ et al (1974) Amputation and adriamycin in primary osteosarcoma. N Engl J Med 291:998-1000
11. Shinozaki T, Watanabe H, Yanagawa T et al (2002) Pirarubicin-based versus doxorubicin-based osteosarcoma chemotherapy. Ann Pharmacother 36:996-999
12. Qi WX, He AN, Tang LN et al (2011) Evaluation of pirarubicin-cisplatin chemotherapy in the treatment for refractory and recurrent high-grade osteosarcoma: experience of a single institute. Med Oncol. doi: 10.1007/s12032-011-0021-y
13. Berrak SG, Pearson M, Berberoglu S et al (2005) High-dose ifosfamide in relapsed pediatric osteosarcoma: therapeutic effects and renal toxicity. Pediatr Blood Cancer 44:215-219
14. Bhalla KN (2003) Microtubule-targeted anticancer agents and apoptosis. Oncogene 22:9075-9086
15. Sudo T, Nitta M, Saya H et al (2004) Dependence of paclitaxel sensitivity on a functional spindle assembly checkpoint. Cancer Res 64:2502-2508
16. Masuda A, Maeno K, Nakagawa T et al (2003) Association between mitotic spindle checkpoint impairment and susceptibility to the induction of apoptosis by anti-microtubule agents in human lung cancers. Am J Pathol 163:1109-1116
17. Chen JG, Horwitz SB (2002) Differential mitotic responses to microtubule-stabilizing and -destabilizing drugs. Cancer Res 62:1935-1938
18. Liu SY, Song SX, Lin L et al (2010) Molecular mechanism of cell apoptosis by paclitaxel and pirarubicin in a human osteosarcoma cell line. Chemotherapy 56:101-107
19. Wilkins RM, Cullen JW, Odom L et al (2003) Superior survival in treatment of primary nonmetastatic pediatric osteosarcoma of the extremity. Ann Surg Oncol 10:498-507
20. Therasse P, Arbuck SG, Eisenhauer EA et al (2000) New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 92:205-216
21. Grignani G, Palmerini E, Dileo P et al (2012) A phase II trial of sorafenib in relapsed and unresectable high-grade osteosarcoma after failure of standard multimodal therapy: an Italian Sarcoma Group study. Ann Oncol 23(2):508-516
22. Geoerger B, Chisholm J, Le Deley MC et al (2011) Phase II study of gemcitabine combined with oxaliplatin in relapsed or refractory paediatric solid malignancies: an innovative therapy for children with Cancer European Consortium Study. Eur J Cancer 47:230-238
23. Berger M, Grignani G, Ferrari S et al (2009) Phase 2 trial of two courses of cyclophosphamide and etoposide for relapsed high-risk osteosarcoma patients. Cancer 115:2980-2987
24. Rodriguez-Galindo C, Daw NC, Kaste SC et al (2002) Treatment of refractory osteosarcoma with fractionated cyclophosphamide and etoposide. J Pediatr Hematol Oncol 24:250-255
25. Ferguson WS, Goorin AM (2001) Current treatment of osteosarcoma. Cancer Invest 19:292-315